MetaVia's DA-1726 cuts liver fat 68% versus placebo in interim Phase 1 data

PUBT · 1d ago
MetaVia's DA-1726 cuts liver fat 68% versus placebo in interim Phase 1 data
  • MetaVia reported positive interim Phase 1 results for DA-1726, showing significant liver fat reduction, weight loss and improved blood sugar control.
  • Results were presented November 4, 2026, at the Precision Liver Symposium, covering otherwise healthy adults with obesity treated for 16 weeks.
  • One serious vomiting event was considered possibly treatment-related; the participant recovered, with no gastrointestinal events causing study discontinuation.
  • A 48-week Phase 2 trial targeting up to 150 patients with metabolic dysfunction-associated and alcohol-associated liver disease is planned for second-half 2027.
  • Full Phase 1 Part 3A and Part 3B data are expected in the first quarter of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metavia Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611050855PR_NEWS_USPR_____NY89318) on November 05, 2026, and is solely responsible for the information contained therein.